<div id="readability-page-1" class="page"><div> <div> , /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ImmunityBio, Inc. (NASDAQ: IBRX). Shareholders who purchased shares of IBRX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/immunitybio-inc-loss-submission-form/?id=186861&amp;from=4 CLASS PERIOD: January 19, 2026 to March 24, 2026 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) defendant Soon-Shion materially overstated Anktiva's capabilities; and (2) as a result, defendants' statements about ImmunityBio's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. DEADLINE: May 26, 2026 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/immunitybio-inc-loss-submission-form/?id=186861&amp;from=4 NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of IBRX during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is May 26, 2026. There is no cost or obligation to you to participate in this case. WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: The Gross Law Firm 15 West 38th Street, 12th floor New York, NY, 10018 Email: [email protected] Phone: (646) 453-8903 SOURCE The Gross Law Firm <img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTI2Jk5ld3NJdGVtSWQ9Tlk2NTY0MyZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MjYwOTAwUFJfTkVXU19VU1BSX19fX19OWTY1NjQz?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTI2Jk5ld3NJdGVtSWQ9Tlk2NTY0MyZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MjYwOTAwUFJfTkVXU19VU1BSX19fX19OWTY1NjQz"/></div> </div></div>

IBRX

IBBQ

LABU

LABD

The Gross Law Firm reminds ImmunityBio, Inc. (NASDAQ: IBRX) shareholders of a lead plaintiff deadline on May 26, 2026, for a class action lawsuit. Shareholders who purchased shares between January 19, 2026, and March 24, 2026, are encouraged to register for potential lead plaintiff appointment due to allegations of misleading statements by the company. Participation in the case incurs no cost.

prnewswire

ImmunityBio

SPDR S&P Biotech

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

Direxion S&P Biotech Bear 3X

09:00 ETThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 26, 2026 in ImmunityBio, Inc. Lawsuit - IBRX